PHT Corporation Delivers Unique Rater Training Programs to Improve Instrument Reliability, Data Quality and Outcomes
Improves data quality and regulatory compliance by combining scientific training with innovative electronic implementation of instruments
BOSTON, Mass. and GENEVA, Switzerland – The pharmaceutical industry is further optimizing the collection of high quality electronic patient reported outcomes (ePROs) data for clinical research, with PHT CorporationRater Training programs. PHT is the leading provider of patient-driven eData systems used to collect outcomes for better clinical research. Three distinct rater training programs developed by the PHT Clinical Science and Consulting team of world-class scientists are now available. The PHT Rater Training courses are based on industry’s need to standardize data collection among clinicians, observers and patients.
Join PHT scientists at a new live webinar February 11 “Make Every Data Point Count: The Importance of Rater Training in Clinical Trials.” Register today: http://bit.ly/14WWnBt
Rater Training for clinician reported outcome (ClinRO), observer reported outcome (ObsRO) and patient reported outcome (PRO) assessments ensures and improves data accuracy by reducing leniency, severity, halo, first impression, and friendship bias. Recommended by global regulators and endorsed by ISPOR, rater training clarifies each instrument’s performance dimensions used in the evaluation system, and advances the detection, perception, and recall of actual performance.
PHT Vice President of Clinical Science and Consulting Dr. Susan M. Dallabrida – one of the 2014 PharmaVOICE 100 most inspiring people in life sciences – explained, “Studies show that clinical experience does not substitute for clinician rater training, which is proven to reduce inter-rater variability and instrument scoring deviations. Rater training for clinicians, caregivers and patients enables standard and uniform use of scales across the trial population and improves data quality leading to an increased signal to noise ratio.” Hear more from Dr. Dallabrida on the value of Rater Training: bit.ly/1zfFXOu
PHT Rater Training programs train clinicians, caregivers and patients on trial instruments and their electronic implementations for optimal data quality. Sponsors are increasingly choosing PHT to provide Rater Training on clinical measures such as:
- Columbia-Suicide Severity Rating Scale (C-SSRS) Screening/Baseline (SB) and Since Last Visit (SLV) Adult and Pediatric versions
- Sheehan Suicidality Tracking Scale (Sheehan-STS)
Only PHT provides a customized IM Science Rater Training Workshop to ensure all clinical trial participants are fully versed on the significance of rater scoring. The Workshop is presented by a PHT Clinical Scientist and includes interactive training and quiz sessions. PHT Rater Training programs are helping trial sponsors increase the value and ROI of their eCOA Systems through improved data quality.
About PHT Corporation
PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for better clinical research. Visit phtcorp.com for more information on PHT. Follow PHT on LinkedIn, Facebook, Twitter, Google+ and YouTube.
Media contact: Brenda Nashawaty, brenda@nashawaty.com, 617-688-3253
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
